We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Endocyte, Inc. (delisted) | NASDAQ:ECYT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.99 | 23.99 | 29.87 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Taylor Beth |
2. Issuer Name
and
Ticker or Trading Symbol
ENDOCYTE INC [ ECYT ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) VP Finance & Chief Acctg Offcr |
3000 KENT AVE, STE A1-100 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
WEST LAFAYETTE, IN 47906 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 12/17/2018 | M | 16073 | A | $3.55 | 72414 | D | |||
Common Stock | 12/17/2018 | M | 5500 | A | $9.86 | 77914 | D | |||
Common Stock | 12/17/2018 | M | 9000 | A | $5.10 | 86914 | D | |||
Common Stock | 12/17/2018 | M | 3750 | A | $3.18 | 90664 | D | |||
Common Stock | 12/17/2018 | M | 9531 | A | $3.21 | 100195 | D | |||
Common Stock | 12/17/2018 | M | 5000 | A | $2.16 | 105195 | D | |||
Common Stock | 12/17/2018 | G | V | 2500 (1) | D | $0 | 102695 | D | ||
Common Stock | 12/17/2018 | G | V | 1250 (2) | D | $0 | 101445 | D | ||
Common Stock | 12/19/2018 | G | V | 3186 (7) | D | $0 | 98259 | D | ||
Common Stock | 12/17/2018 | G | V | 1250 (2) | A | $0 | 1250 | I | By daughter |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock option (right to buy) | $3.55 | 12/17/2018 | M | 16073 | (3) | 2/28/2022 | Common Stock | 16073 | $0 | 0 | D | ||||
Stock option (right to buy) | $9.86 | 12/17/2018 | M | 5500 | (3) | 2/19/2023 | Common Stock | 5500 | $0 | 9132 | D | ||||
Stock option (right to buy) | $5.10 | 12/17/2018 | M | 9000 | (3) | 2/4/2025 | Common Stock | 9000 | $0 | 0 | D | ||||
Stock option (right to buy) | $3.18 | 12/17/2018 | M | 3750 | (4) | 2/4/2026 | Common Stock | 3750 | $0 | 3750 | D | ||||
Stock option (right to buy) | $3.21 | 12/17/2018 | M | 9531 | (5) | 8/18/2026 | Common Stock | 9531 | $0 | 12969 | D | ||||
Stock option (right to buy) | $2.16 | 12/17/2018 | M | 5000 | (6) | 2/2/2027 | Common Stock | 5000 | $0 | 15000 | D |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Taylor Beth
3000 KENT AVE, STE A1-100 WEST LAFAYETTE, IN 47906 |
|
|
VP Finance & Chief Acctg Offcr |
|
Signatures
|
||
/s/ Beth A. Taylor | 12/19/2018 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Endocyte, Inc. (delisted) Chart |
1 Month Endocyte, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions